Document is current
Any future updates will be listed below
-
Authors
Kathman, Stefan G. https://orcid.org/0000-0002-4755-9907
Koo, Seong Joo
Lindsey, Garrett L.
Her, Hsuan-Lin
Blue, Steven M.
Li, Haoxin
Jaensch, Steffen
Remsberg, Jarrett R. https://orcid.org/0000-0002-5234-0168
Ahn, Kay https://orcid.org/0000-0001-9139-1534
Yeo, Gene W. https://orcid.org/0000-0002-0799-6037
Ghosh, Brahma https://orcid.org/0000-0003-2288-8293
Cravatt, Benjamin F. https://orcid.org/0000-0001-5330-3492
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA228436, R35 CA231991)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R01 HG004659)
- License Information
-
More Information
Article History
Received: 29 March 2022
Accepted: 20 January 2023
First Online: 2 March 2023
Competing interests
: B.F.C. is a founder and scientific advisor to Vividion Therapeutics. G.W.Y. is an SAB member of Jumpcode Genomics and a cofounder, a member of the Board of Directors, on the SAB, an equity holder and a paid consultant for Locanabio and Eclipse BioInnovations. G.W.Y. is a visiting professor at the National University of Singapore. G.W.Y.’s interests have been reviewed and approved by the University of California, San Diego, in accordance with its conflict-of-interest policies. The other authors declare no competing interests.
